Your browser doesn't support javascript.
loading
Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index.
Albisinni, Simone; Diamand, Romain; Mjaess, Georges; Aoun, Fouad; Assenmacher, Gregoire; Assenmacher, Christophe; Verhoest, Gregory; Holz, Serge; Naudin, Michel; Ploussard, Guillaume; Mari, Andrea; Minervini, Andrea; Tay, Andrea; Issa, Rami; Roumiguié, Mathieu; Bajeot, Anne Sophie; Simone, Giuseppe; Anceschi, Umberto; Umari, Paolo; Sridhar, Ashwin; Kelly, John; Hendricksen, Kees; Einerhand, Sarah; Sandel, Noah; Sanchez-Salas, Rafael; Colomer, Anna; Quackels, Thierry; Peltier, Alexandre; Montorsi, Francesco; Briganti, Alberto; Teoh, Jeremy Y C; Pradere, Benjamin; Moschini, Marco; Roumeguère, Thierry.
Afiliação
  • Albisinni S; Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Diamand R; Department of Urology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Mjaess G; Department of Urology, Hotel Dieu de France, Beirut, Lebanon.
  • Aoun F; Department of Urology, Hotel Dieu de France, Beirut, Lebanon.
  • Assenmacher G; Department of Urology, Cliniques de l'Europe-Saint Elisabeth, Brussels, Belgium.
  • Assenmacher C; Department of Urology, Cliniques de l'Europe-Saint Elisabeth, Brussels, Belgium.
  • Verhoest G; Department of Urology, CHU Rennes, Rennes, France.
  • Holz S; Department of Urology, CHU Ambroise Paré, Mons, Belgium.
  • Naudin M; Department of Urology, CHU Ambroise Paré, Mons, Belgium.
  • Ploussard G; Department of Urology, La Croix du Sud Hospital, Toulouse, France; Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
  • Mari A; Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi University Hospital, Florence, Italy.
  • Minervini A; Department of Experimental and Clinical Medicine, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi University Hospital, Florence, Italy.
  • Tay A; Department of Urology, Saint Georges Hospital, London, United Kingdom.
  • Issa R; Department of Urology, Saint Georges Hospital, London, United Kingdom.
  • Roumiguié M; Department of Urology, Andrology, and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, Toulouse Cedex, France.
  • Bajeot AS; Department of Urology, Andrology, and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, Toulouse Cedex, France.
  • Simone G; Department of Urology, Regina Elena National Cancer Institute, Rome, Italy.
  • Anceschi U; Department of Urology, Regina Elena National Cancer Institute, Rome, Italy.
  • Umari P; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.
  • Sridhar A; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.
  • Kelly J; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.
  • Hendricksen K; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Einerhand S; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sandel N; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sanchez-Salas R; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Colomer A; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Quackels T; Department of Urology, University Clinics of Brussels, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Peltier A; Department of Urology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Montorsi F; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Briganti A; Vita-Salute San Raffaele University, Milan, Italy.
  • Teoh JYC; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Pradere B; Vita-Salute San Raffaele University, Milan, Italy.
  • Moschini M; S.H. Ho Urology Center, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
  • Roumeguère T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
J Endourol ; 36(6): 785-792, 2022 06.
Article em En | MEDLINE | ID: mdl-35109696
ABSTRACT
Background and

Objective:

The Clavien-Dindo Classification (CDC) only reports the postoperative complication of highest grade. It is thus of limited value for radical cystectomy, after which patients usually experience multiple complications. The Comprehensive Complication Index (CCI) is a novel scoring system, which incorporates all postoperative events in one single value. The study aimed to adopt the CCI for the evaluation of complications in patients undergoing robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) and explore its advantages in the analysis of the morbidity of RARC with ICUD. Patients and

Methods:

A multicentric cohort of 959 patients undergoing RARC+ICUD between 2015 and 2020, whose complications are encoded in local prospective registries. Postoperative complications at 30 days were assessed using both the CDC and CCI. The CCI was calculated using an online tool (assessurgery.com). Risk factors for overall, major complications (CDC ≥III), and CCI were evaluated using uni- and multivariable logistic and linear regressions. To analyze the potential advantage of using the CCI in clinical trials, a sample size calculation of a hypothetic clinical trial was performed using as endpoint reduction of morbidity with either the CDC or CCI.

Results:

Overall, 885 postoperative complications were reported in 507 patients (53%). The CCI improved the definition of postoperative morbidity in 22.6% of patients. Male sex and neobladder were associated with major complications and to a significant increase in CCI on adjusted regressions. In a hypothetical clinical trial, 80 patients would be needed to demonstrate a ten-point reduction in CCI, compared with 186 needed to demonstrate an absolute risk reduction of 20% in overall morbidity using the CDC.

Conclusion:

CCI improves the evaluation of postoperative morbidity by considering the cumulative aspect of complications compared with the CDC. Implementing the CCI for radical cystectomy would help reducing sample sizes in clinical trials. Clinical Trial Registration number NCT03049410.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Derivação Urinária / Neoplasias da Bexiga Urinária / Robótica / Procedimentos Cirúrgicos Robóticos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: J Endourol Assunto da revista: UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Derivação Urinária / Neoplasias da Bexiga Urinária / Robótica / Procedimentos Cirúrgicos Robóticos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: J Endourol Assunto da revista: UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Bélgica